Literature DB >> 20523342

IGF2BP2 variations influence repaglinide response and risk of type 2 diabetes in Chinese population.

Qiong Huang1, Ji-ye Yin, Xing-ping Dai, Qi Pei, Min Dong, Zhi-guang Zhou, Xi Huang, Min Yu, Hong-hao Zhou, Zhao-qian Liu.   

Abstract

AIM: To investigate whether the insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) rs1470579 and rs4402960 polymorphisms are associated with the development of type 2 diabetes mellitus (T2DM) and the repaglinide therapeutic efficacy in Chinese T2DM patients.
METHODS: A case-control study of a total of 350 patients with T2DM and 207 healthy volunteers was conducted to identify their genotypes for the IGF2BP2 rs1470579 and rs4402960 polymorphisms using a polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. Forty-two patients were randomly selected to undergo an 8-week repaglinide treatment (3 mg/d). Fasting plasma glucose (FPG), postprandial plasma glucose (PPG), glycated hemoglobin (HbAlc), fasting serum insulin (FINS), postprandial serum insulin (PINS), homeostasis model assessment for insulin resistance (HOMA-IR), serum triglyceride, total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-c), and high-density lipoprotein-cholesterol (HDL-c) were determined before and after repaglinide treatment.
RESULTS: The frequencies of the IGF2BP2 rs1470579 C allele and the rs4402960 T allele were higher in T2DM patients than in healthy controls (P<0.05 and P<0.001, respectively). The effects of the repaglinide treatment on FPG (P<0.05) and PPG (P<0.05) were reduced in patients with the rs1470579 AC+CC genotypes compared with AA genotype carriers. Patients with the rs4402960 GT+TT genotypes exhibited an enhanced effect of repaglinide treatment on PINS (P<0.01) compared with GG genotype subjects.
CONCLUSION: The IGF2BP2 rs1470579 and rs4402960 polymorphisms may be associated with the development of T2DM, and these polymorphisms may affect the therapeutic efficacy of repaglinide in Chinese T2DM patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20523342      PMCID: PMC4002970          DOI: 10.1038/aps.2010.47

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  31 in total

1.  Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.

Authors:  Mikko Niemi; Janne T Backman; Lauri I Kajosaari; Julian B Leathart; Mikko Neuvonen; Ann K Daly; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen
Journal:  Clin Pharmacol Ther       Date:  2005-06       Impact factor: 6.875

2.  Safety of type 2 diabetes treatment with repaglinide compared with glibenclamide in elderly people: A randomized, open-label, two-period, cross-over trial.

Authors:  Giuseppe Papa; Viviana Fedele; Maria Rosaria Rizzo; Marisa Fioravanti; Carmelo Leotta; Sebastiano Bruno Solerte; Francesco Purrello; Giuseppe Paolisso
Journal:  Diabetes Care       Date:  2006-08       Impact factor: 19.112

3.  A genome-wide association study identifies novel risk loci for type 2 diabetes.

Authors:  Robert Sladek; Ghislain Rocheleau; Johan Rung; Christian Dina; Lishuang Shen; David Serre; Philippe Boutin; Daniel Vincent; Alexandre Belisle; Samy Hadjadj; Beverley Balkau; Barbara Heude; Guillaume Charpentier; Thomas J Hudson; Alexandre Montpetit; Alexey V Pshezhetsky; Marc Prentki; Barry I Posner; David J Balding; David Meyre; Constantin Polychronakos; Philippe Froguel
Journal:  Nature       Date:  2007-02-11       Impact factor: 49.962

4.  A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development.

Authors:  J Nielsen; J Christiansen; J Lykke-Andersen; A H Johnsen; U M Wewer; F C Nielsen
Journal:  Mol Cell Biol       Date:  1999-02       Impact factor: 4.272

5.  The RNA-binding protein, Vg1RBP, is required for pancreatic fate specification.

Authors:  Francesca M Spagnoli; Ali H Brivanlou
Journal:  Dev Biol       Date:  2006-04-15       Impact factor: 3.582

6.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

7.  Limitation of the validity of the homeostasis model assessment as an index of insulin resistance in Korea.

Authors:  Eun Seok Kang; Yong Seok Yun; Seok Won Park; Hyeung Jin Kim; Chul Woo Ahn; Young Duk Song; Bong Soo Cha; Sung Kil Lim; Kyung Rae Kim; Hyun Chul Lee
Journal:  Metabolism       Date:  2005-02       Impact factor: 8.694

8.  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030.

Authors:  Sarah Wild; Gojka Roglic; Anders Green; Richard Sicree; Hilary King
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

9.  Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.

Authors:  Richa Saxena; Benjamin F Voight; Valeriya Lyssenko; Noël P Burtt; Paul I W de Bakker; Hong Chen; Jeffrey J Roix; Sekar Kathiresan; Joel N Hirschhorn; Mark J Daly; Thomas E Hughes; Leif Groop; David Altshuler; Peter Almgren; Jose C Florez; Joanne Meyer; Kristin Ardlie; Kristina Bengtsson Boström; Bo Isomaa; Guillaume Lettre; Ulf Lindblad; Helen N Lyon; Olle Melander; Christopher Newton-Cheh; Peter Nilsson; Marju Orho-Melander; Lennart Råstam; Elizabeth K Speliotes; Marja-Riitta Taskinen; Tiinamaija Tuomi; Candace Guiducci; Anna Berglund; Joyce Carlson; Lauren Gianniny; Rachel Hackett; Liselotte Hall; Johan Holmkvist; Esa Laurila; Marketa Sjögren; Maria Sterner; Aarti Surti; Margareta Svensson; Malin Svensson; Ryan Tewhey; Brendan Blumenstiel; Melissa Parkin; Matthew Defelice; Rachel Barry; Wendy Brodeur; Jody Camarata; Nancy Chia; Mary Fava; John Gibbons; Bob Handsaker; Claire Healy; Kieu Nguyen; Casey Gates; Carrie Sougnez; Diane Gage; Marcia Nizzari; Stacey B Gabriel; Gung-Wei Chirn; Qicheng Ma; Hemang Parikh; Delwood Richardson; Darrell Ricke; Shaun Purcell
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

10.  A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants.

Authors:  Laura J Scott; Karen L Mohlke; Lori L Bonnycastle; Cristen J Willer; Yun Li; William L Duren; Michael R Erdos; Heather M Stringham; Peter S Chines; Anne U Jackson; Ludmila Prokunina-Olsson; Chia-Jen Ding; Amy J Swift; Narisu Narisu; Tianle Hu; Randall Pruim; Rui Xiao; Xiao-Yi Li; Karen N Conneely; Nancy L Riebow; Andrew G Sprau; Maurine Tong; Peggy P White; Kurt N Hetrick; Michael W Barnhart; Craig W Bark; Janet L Goldstein; Lee Watkins; Fang Xiang; Jouko Saramies; Thomas A Buchanan; Richard M Watanabe; Timo T Valle; Leena Kinnunen; Gonçalo R Abecasis; Elizabeth W Pugh; Kimberly F Doheny; Richard N Bergman; Jaakko Tuomilehto; Francis S Collins; Michael Boehnke
Journal:  Science       Date:  2007-04-26       Impact factor: 47.728

View more
  16 in total

Review 1.  The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.

Authors:  N van Leeuwen; J J Swen; H-J Guchelaar; L M 't Hart
Journal:  Clin Pharmacokinet       Date:  2013-10       Impact factor: 6.447

2.  Genetics of type 2 diabetes.

Authors:  Omar Ali
Journal:  World J Diabetes       Date:  2013-08-15

Review 3.  The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers.

Authors:  Jinyan Wang; Lijuan Chen; Ping Qiang
Journal:  Cancer Cell Int       Date:  2021-02-10       Impact factor: 5.722

4.  Personalized medicine of type 2 diabetes.

Authors:  Weiping Jia
Journal:  Front Med       Date:  2013-03       Impact factor: 4.592

Review 5.  Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data.

Authors:  Gaia Chiara Mannino; Giorgio Sesti
Journal:  Mol Diagn Ther       Date:  2012-10       Impact factor: 4.074

Review 6.  The Roles of Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 in Cancer and Cancer Stem Cells.

Authors:  Junguo Cao; Qingchun Mu; Haiyan Huang
Journal:  Stem Cells Int       Date:  2018-03-15       Impact factor: 5.443

7.  Association of Genetic Variants in IGF2-Related Genes With Risk of Metabolic Syndrome in the Chinese Han Population.

Authors:  Weiwei Gui; Julong Liang; Xihua Lin; Nanjing Shi; Yiyi Zhu; Bowen Tan; Hong Li
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-20       Impact factor: 5.555

8.  Association of follicle-stimulating hormone receptor polymorphisms with ovarian response in Chinese women: a prospective clinical study.

Authors:  Yuanliang Yan; Zhicheng Gong; Lu Zhang; Yanping Li; Xiong Li; Lin Zhu; Lunquan Sun
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

9.  Validation of type 2 diabetes risk variants identified by genome-wide association studies in Han Chinese population: a replication study and meta-analysis.

Authors:  Yi-Cheng Chang; Pi-Hua Liu; Yu-Hsiang Yu; Shan-Shan Kuo; Tien-Jyun Chang; Yi-Der Jiang; Jiun-Yi Nong; Juey-Jen Hwang; Lee-Ming Chuang
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

10.  Association between IGF2BP2 Polymorphisms and Type 2 Diabetes Mellitus: A Case-Control Study and Meta-Analysis.

Authors:  Ping Rao; Hao Wang; Honghong Fang; Qing Gao; Jie Zhang; Manshu Song; Yong Zhou; Youxin Wang; Wei Wang
Journal:  Int J Environ Res Public Health       Date:  2016-06-09       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.